Podcasts about Monty

When we think of 1940, we picture Dunkirk, the fall of France and the BEF racing for the Channel. But behind the headlines were real officers making real decisions — the brigadiers. Too senior to ignore, not quite famous enough to be remembered. In this episode, my friend and part-time co-host Chris Brice talks to military historian Dr Phil McCarty about his new book Point of Failure: British Brigadiers in France and Norway, 1940. They explore who these men were, how they were selected, and why some rose to greatness while others quietly vanished after the débâcle of 1940. Expect discussion of staff college bottlenecks, Monty and Brooke's patronage, public school myths, territorials, and why the brigadiers of Normandy look both similar to — and subtly different from — their 1940 predecessors. Plus some cracking stories along the way. If you enjoy British Army history told through real people rather than map arrows, you'll enjoy this one. Purchase Phil's book here - https://www.helion.co.uk/military-history-books/point-of-failure-british-brigadiers-in-france-and-norway-1940.php  Discover Chris Brice's books here - https://www.helion.co.uk/people/christopher-brice.php  Join my mailing list for a free eBook about the Zulu War - https://redcoathistory.com/ 

Detroit Lions Make A Statement When They Had To The Detroit Lions did not just beat the Dallas Cowboys. They answered a question the rest of the NFL was starting to whisper: could this team still reach the gear it showed last year when everything mattered. A 44–30 win over Dallas at Ford Field in a must win spot is not perfection, but it is proof of concept. This is what the Lions offense is supposed to look like when it breathes, and what this defense looks like when it steals possessions instead of just surviving. Jared Goff, Jahmyr Gibbs and an Offensive Line That Finally Settled This felt like a reset game for Jared Goff. After weeks of interior chaos and happy feet, he played like a quarterback who trusted what was in front of him, finishing with a 121 passer rating and command of the entire field. He did not just lock onto Amon Ra St. Brown. He spread it around. St. Brown went 6 for 92 on one good ankle. Jameson Williams added 7 for 96 in what might be his most complete game as a pro. The star, though, continues to be Jahmyr Gibbs. He is no longer just a fun wrinkle in the playbook. He is the problem defenses cannot solve. Seventy seven receiving yards, a series of ankle erasers in space, and the constant threat that any touch might become a house call. This is the first Lions player since Barry Sanders who genuinely makes you lean forward every time he has the ball. Quietly, the big shift up front was Miles Frazier. Once the rookie stepped in at left guard for Tristan Colon, the protection and run fits stopped looking like a fire drill. Frazier buried people on duo and inside zone, climbed to the second level with bad intentions, and gave both Goff and David Montgomery room to operate. Monty responded with 60 hard rushing yards and looked far closer to the back we saw last season than the guy fighting for air against Philadelphia. If this is who the offensive line can be with Frazier settling in and the tackles relatively healthy, Detroit's playbook opens back up. Shot plays to Williams, option routes for St. Brown, and Gibbs isolated on linebackers is how the Lions offense stresses an entire defense. Defense, Special Teams and the NFC Playoff Picture The Lions defense did not dominate Dallas statistically, but it did what great units do in big games. It turned the ball over. Fourteen points came directly off Cowboys mistakes. Jack Campbell flew around again, DJ Reed battled with CeeDee Lamb until the concussion, and the front made Dak Prescott uncomfortable enough to force high risk throws. Special teams finally flipped a field too. Tom Kennedy looked like he had been waiting five years for those returns, hitting seams at full speed and giving the offense short grass it has been missing all season. That is how complementary football is supposed to look in a real playoff race. In the NFC playoff picture, the win keeps the Detroit Lions alive for more than just a wild card berth. It keeps pressure on Green Bay and Chicago, and it turns next week's trip to play the Los Angeles Rams into a leverage game instead of a funeral. Run the ball the way Carolina just did against the Rams, protect Goff the way they did against Dallas, and Detroit can turn this one statement into the start of a December run. https://www.youtube.com/watch?v=LvYN107viHw Get yourself a Classic Detroit t-shirt here! Don't miss our great merch selection in the Detroit Lions Podcast store. Looking for the relief that CBD products can bring? Click here: https://bit.ly/2XzawlG Get your Lions Gear at: https://bit.ly/2Ooo5Px As an Amazon Associate we earn from qualifying purchases made here: https://amzn.to/36e2ZfD Donate Direct at: https://bit.ly/2qnEtFj Join the Patreon Crew at: https://bit.ly/2bgQgyj #DetroitLions, #Lions, #DetroitLionsPodcast, #OnePride, #LionsWin, #LionsMakeAStatement #GoffLockedIn #GibbsElectric #FrazierBreakout #LionsPlayoffPush #JamoStepsUp #StBrownBattles #CowboysFallInDetroit #ComplementaryFootball #FordFieldEnergy Learn more about your ad choices. Visit megaphone.fm/adchoices

In this explosive episode of Joe Oltmann Untamed, Patrick Byrnes drops intel so shocking it left General Michael Flynn visibly shaken—revealing spies, traitors, and the deep rot threatening America's future. Joe tears into Colorado's clown-show leadership, from Governor Polis to media lapdog Kyle Clark, exposing the treasonous betrayal of the people while taxpayer dollars vanish into open-border chaos and radical agendas. It's a no-holds-barred wake-up call on how American voices are being stolen at the ballot box and beyond.Then, meet the antidote: Tennessee gubernatorial candidate Monty Fritts—a Christian constitutional warrior running on Liberty & Less Government. From slashing the state's runaway 59% budget explosion and phasing out the grocery tax to ending funding for illegal aliens, killing geoengineering experiments, and demanding every state bureaucrat pass a Constitutional competency test, Monty lays out his bold plan to dismantle bureaucracy, defend the Second Amendment without apology, and return Tennessee to its God-given, America-First foundation. This is the kind of fearless leadership Polis and Walz will never have.The fight intensifies as Project Veritas exposes Ilhan Omar-linked ballot harvesting, Tim Walz whines about being called out, and viral clips show fed-up veterans and citizens pushing back against the invasion. Border Czar Tom Homan delivers the mic-drop line every patriot needs to hear. This is raw, unfiltered truth for a nation under siege—don't miss it.

The planning for Operation Husky was anything but smooth and comprehensive. Everyone had a dog in this fight, but in the end, Monty won. Meanwhile, Mussolini is tempted to pull out of the war. Learn more about your ad choices. Visit megaphone.fm/adchoices

As always, there are still a TON of questions that need to be answered with this franchise. Who caused the Bite of 83? Why does Monty hate Bonnie? And what does David Afton's facorite show have to do with the Mimic? Join Game Theory host Tom as he answers ALL your burning questions in today's episode!

Jones and Keefe were joined by Drew Carter, Boston Celtics play-by-play announcer, to discuss the state of the team. Before continued to talked about the Celtics and the current state of the Boston Bruins, the guys answered a Four-Pack of questions.

Monty Nero the acclaimed creator of Death Sentence (Titan Comics) and Marvel's Hulk & X-Men is back to tear into the megacity shadows with the Kickstarter of Chrome Roses: Cyberpunk Trilogy  Book 2! We're returning to The Tract,  a rain-slicked dystopian metropolis where detective Kramm and punk vigilante Teo battle viruses, corporate corruption, and tech billionaires who literally own your emotions. Book 1 set the stage… now Book 2 cranks the stakes to a whole new level! In this interview, Monty drops: How Book 2 builds on the chaos and intrigue of Book 1 Secrets of crafting noir cyberpunk worlds that hit hard Art style evolutions and the darker tones of this chapter Kickstarter campaign exclusives for returning and new backers Hints at where the trilogy is heading

Kirt & Mr. Sal discuss Season 1 Episode 3 of Bad Monkey in which Monty made paella. Shoe Hammer some Show Hoppers into your day! Website: showhoppers.com Twitter: https://twitter.com/ShowHoppers Contact Us: showhopperspodcast@gmail.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On Episode 602 of Spittin' Chiclets, the crew welcomes Hall of Famer Luc Robitaille for an all-time interview, but not before chewing through one of the wildest stretches of hockey chaos we've seen yet. We've got Peakin' Episode 3 dropping, NHL Coast to Coast launching Thursday at 7PM ET for our Canadian listeners, and Prime Monday Night Hockey in the Yacht Club as the Lightning and Leafs head in opposite directions. Toronto is hanging on for dear life in the East but with a big win in Florida could the Snoop Dogg shirts be dropping? Trade winds are swirling around Binnington vs Monty, Sheldon Keefe is losing his mind after the Dillon incident, and the Capitals are buzzing with five straight wins. Bedard highlights, Mackinnon history, Ozzy Wiesblatt's emotional moment, Olympic rink drama, Jesper Wallstedt shutting the league down, OBJ teaching Finance 101, Kevin Dineen's courageous announcement, Biz promising blood, and RA's World. Luc Robitaille. Strap in. This is an Episode you won't want to miss. 00:00:00 - START 00:00:31 - CHICLES UPDATES 00:10:04 - OLYMPICS 00:27:59 - BINNINGTON BEEF 00:34:35 - LEAFS VS TAMPA 00:43:51 - BRENDAN DILLON INJURY 00:48:19 - LUC ROBITAILLE INTERVIEW 02:25:22 - BUBLÉ VS SERAVALLI 02:27:48 - RA's WORLD 03:06:10 - ETC. Support the Show: DISCOVER: Get cash back on every purchase with the Discover It card. Learn more at discover.com/creditcard https://www.discover.com/nhl GAMETIME: Download the Gametime app today and use code CHICLETS for $20 off your first purchase PRIME MONDAY NIGHT HOCKEY: Prime Monday Night Hockey is available free to Prime members in Canada. Start your free trial: www.primevideo.com  For the full Prime Monday Night Hockey schedule, visit https://www.primevideo.com/salp/nhl. NOBULL: Visit https://nobullproject.com/chiclets for 40% off your entire order.  SPORTCLIPS: Try one of the Holiday Playmaker Scents! Available until December 27 at participating locations only and where permitted by law. Sport Clips. It's a Game Changer. RHOBACK: Use code CHICLETS on https://rhoback.com for 20% off your first purchase through the end of this weekYou can find every episode of this show on Apple Podcasts, Spotify or YouTube. Prime Members can listen ad-free on Amazon Music. For more, visit barstool.link/schiclets

(00:00-3:33) Jim Montgomery making his glorious return to Boston tonight. Audio of Monty talking about the mixed emotions of going back to Boston. Big road trip, Doug, here we go. Why are the Blues favored tonight?(3:41-12:22) Those are Jackson's words, not mine. Can't get anything past Movie Boi. I'm just Pervert Boi. Oh, these people. Watching people watch movies.(12:32-22:45) Visit Pine Lawn with a keen observation in the YouTube chat. Can't afford to lose a catcher. Audio of Harold Reynolds giving his thoughts on Wilson Contreras. Tim's Cowherdian take on the upcoming Cardinal season. Ultimate vs Penultimate.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Monty Pal and Dr. Jason Westin discuss the federal funding climate for cancer research and the persistent problem of drug shortages, two of the major concerns facing the oncology community in 2026. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I am your host, Dr. Monty Pal. I am a medical oncologist and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. There are always multiple challenges facing oncologists, and today, we discuss two of them that really stand out for 2026: threats to federal funding for cancer research and the persistent problem of drug shortages. I am thrilled to welcome Dr. Jason Westin, who believes that one way to meet these challenges is to get oncologists more involved in advocacy, and he will share some strategies to help us meet this moment in oncology. Dr. Westin is a professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, but he actually wears a lot of hats within ASCO. He is a member of the Board of Directors and has also previously served as chair of ASCO's Government Relations Committee. And he is also one of the inaugural members of ASCO's Political Action Committee, or PAC. He has testified before Congress about drug shortages and many other issues. Dr. Westin, I am really excited to have you on the podcast today and dive into some of these elements that will really impact our community in 2026. Thanks so much for joining us today. Dr. Jason Westin: Thank you for having me. Dr. Monty Pal: You've had such a range of experience. I already alluded to you testifying before Congress. You've actually run for office before. You wear so many different hats. I'm used to checking my PubMed every other day and seeing a new paper out from you and your group, and you publish in the New England Journal [of Medicine] on practice-setting standards and the diseases that you treat. But you've also done all this work in the domain of advocacy. I can't imagine that balancing that is easy. What has sort of motivated you on the advocacy front? Dr. Jason Westin: Advocacy to me is another way to apply our skills and help more people than just those that you're sitting across from at the time. Clinical research, of course, is a tool to try and take what we know and apply it more broadly to people that you'll never meet. And advocacy, I think, can do the same thing, where you can have a conversation with a lawmaker, you can advocate for a position, and that hopefully will help thousands or maybe even more people down the road who you'd never get to directly interact with. And so, I think it's a force multiplier in the same way that research can be. And so, I think advocacy is a wonderful part of how doctors care for our patients. And it's something that is often difficult to know where to start, but once people get into advocacy, they can see that the power, the rewarding nature of it is attractive, and most people, once they get going, continue with that through the rest of their career. Dr. Monty Pal: So, I'll ask you to expand on that a little bit. We have a lot of our younger ASCO members listening to this podcast, folks that are just starting out their careers in clinical practice or academia. Where does that journey begin? How do you get to the point that you're testifying in front of Congress and taking on these bigger sort of stances for the oncology community? Dr. Jason Westin: Yeah, with anything in medicine and in our careers, you have to start somewhere. And often you start with baby steps before you get in front of a panel of senators or other high-profile engagement opportunities. But often the first setting for junior colleagues to be engaged is doing things – we call them "Hill Days" – but basically being involved in kind of low-stakes meetings where you're with a group of peers, some of whom have done this multiple times before, and can get engaged talking to members of representatives' offices, and doing so in a way where it's a natural conversation that you're telling a story about a patient in your clinic, or that you're telling a personal experience from a policy that impacted your ability to deliver optimal care. It sounds stressful, but once you're doing it, it's not stressful. It's actually kind of fun. And it's a way that you can get comfort and skill with a group of peers who are there and able to help you. And ASCO has a number of ways to do that, both at the federal level, there's the Hill Day where we each April have several hundred ASCO members travel to Capitol Hill. There's also state engagement that can be done, so-called visiting at home, when representatives from the U.S. Congress or from state legislators are back in district. You can meet with your own representatives on behalf of yourself, on behalf of your organization, and advocate for policies in a way that can be beneficial to your patients. But those initial meetings that are in the office often they're low stakes because you could be meeting not with the representative but with their staff. And that staff sometimes is as young or even younger than our junior colleagues. These sometimes can be people in their 20s, but they're often extremely knowledgeable, extremely approachable, and are used to dealing with people who are new to advocacy. But they actually help make decisions within the office. So it's not a waste of time. It's actually a super useful way to engage. So, it's that first step of anything in life. The activation energy is always high to do something new. But I'd encourage people who are listening to this podcast already having some level of interest about it to explore ways that they could engage more. Dr. Monty Pal: You know, I have to tell you, I'm going to riff on what you just said for a second. ASCO couldn't make it any easier, I think, for folks to participate and get involved. So, if you're listening to this and scratching your head and thinking, "Well, where do I begin? How do I actually sign on for that meeting with a local representative?" Go to the ASCO ACT Network website. And I'll actually talk to our producer, Geraldine, to make sure we've got a link to that somewhere associated with this podcast after it's published, Jason, but I actually keep that on my browser and it's super easy. I check in there every now and then and see if there's any new policy or legislation that ASCO, you know, is sort of taking a stance on, and it gives me some fodder for conversation with my local representatives too. I mean, it's just an awesome, awesome vehicle. I'm going to segue right from there right to the issues. So, you and I are both at academic centers. You know, I think this is something that really pervades academia and enters into implications for general clinical practice. There's been this, you know, massive sort of proposal for decreased funding to the NCI and to the NIH and so forth. Tell us what ASCO is doing in that regard, and tell us perhaps how our community can help. Dr. Jason Westin: We live in interesting times, and I think that may be an understatement x 100. But obviously investments in research are things that when you're at an academic center, you see and feel that as part of your daily life. Members of Congress need to be reminded of that because there's a lot of other competing interests out there besides investing in the future through research. And being an elected representative is a hard job. That is something where you have to make difficult choices to support this, and that may mean not supporting that. And there's lots of good things where our tax dollars could be spent. And so, I'm sympathetic to the idea that there's not unlimited resources. However, ASCO has done an excellent job, and ASCO members have led the charge on this, of stating what research does, what is the benefit of research, and therefore why should this matter to elected representatives, to their staff, and to those people that they're elected to serve. And ASCO has led with a targeted campaign to basically have that message be conveyed at every opportunity to elected representatives. And each year on Hill Day, one of the asks that we have is to continue to support research: the NCI, NIH, ARPA-H, these are things that are always in the asks to make sure that there's appropriate funding. But effectively playing offense by saying, "It's not just a number on a sheet of paper, this is what it means to patients. This is what it means to potentially your loved ones in the future if you are in the opposite situation where you're not on the legislative side, but you're in the office receiving a diagnosis or receiving a difficult piece of news." We only have the tools we have now because of research, and each breakthrough has been years in the making and countless hours spent funded through the engine of innovation: clinical research and translational research. And so ASCO continues to beat that drum. You mentioned earlier the ACT Network. Just to bring that back again is a very useful, very easy tool to communicate to your elected representatives. When you sign up on the ASCO ACT website, you get emails periodically, not too much, but periodically get emails of, "This is a way you can engage with your lawmakers to speak up for this." And as you said, Monty, they make it as easy as possible. You click the button, you type in your address so that it figures out who your elected representatives are, and then it will send a letter on your behalf after like five clicks to say, "I want you to support research. I want you to vote for this particular thing which is of interest to ASCO and by definition to members of ASCO." And so the ACT Network is a way that people listening can engage without having to spend hours and significant time, but just a few clicks can send that letter to a representative in Congress. And the question could be: does that matter? Does contacting your senator or your elected representative do anything? If all they're hearing is somebody else making a different argument and they're hearing over and over again from people that want investments in AI or investments in something else besides cancer research, whatever it is, they may think that there's a ground shift that people want dollars to be spent over here as opposed to at the NIH or NCI or in federally funded research. It is important to continue to express the need for federal funding for our research. And so, it really is important for folks to engage. Dr. Monty Pal: 100%. One of the things that I think is not often obvious to a lot of our listeners is where the support for clinical trials comes from. You know, you've obviously run the whole gamut of studies as have I. You know, we have our pharmaceutical company-sponsored studies, which are in a particular bucket. But I would say that there's a very important and critical subset of studies that are actually government funded, right? NCI-funded clinical trials. If you don't mind, just explain to our audience the critical nature of the work that's being done in those types of studies and if you can, maybe compare and contrast the studies that are done in that bucket versus perhaps the pharmaceutical bucket. Dr. Jason Westin: Both are critical, and we're privileged that we have pharma studies that are sponsored and federally funded clinical research. And I think that part of a healthy ecosystem for us to develop new breakthroughs has a need for both. The pharma sponsored studies are done through the lens of trying to get an approval for an agent that's of interest so that the pharma company can then turn around and use that outside of a clinical trial after an FDA approval. And so those studies are often done through the lens of getting over the finish line by showing some superiority over an existing treatment or in a new patient population. But they're done through that lens of kind of the broadest population and sometimes relatively narrow endpoints, but to get the approval so that then the drug can be widely utilized. Clinical trials done through cooperative groups are sometimes done to try and optimize that or to try and look at comparative things that may not be as attractive to pharma studies, not necessarily going for that initial approval, but the fine tuning or the looking at health outcomes or looking at ensuring that we do studies in representative populations that may not be as well identified on the pharma sponsored trials, but basically filling out the gaps in the knowledge that we didn't gain from the initial phase 3 trial that led to the approval. And so both are critical. But if we only do pharma sponsored trials, if we don't fund federally supported research and that dries up, the fear I have, and many others have, is that we're going to be lacking a lot of knowledge about the best ways to use these great new therapies, these new immune therapies, or in my team, we do a lot of clinical trials on CAR T-cell therapies. If we don't have federally funded research to do the important clinical studies, we'll be in the dark about the best ways to use these drugs, and that's going to be a terrible shame. And so we really do need to continue to support federal research. Dr. Monty Pal: Yeah, there are no softball questions on this podcast, but I think everybody would be hard pressed to think that you and I would come on here and say, "Well, no, we don't need as much money for clinical trials and NCI funding" and so forth. But I think a really challenging issue to tackle, and this is something we thought to ask you ahead of the podcast, is what to do about the general climate of, you know, whether it's academic research or clinical practice here that seems to be getting some of our colleagues thinking about moving elsewhere. I've actually talked to a couple of folks who are picking up and moving to Europe for a variety of considerations, other continents, frankly. The U.S. has always been a leader when it comes to oncology research and, one might argue, research in general. Some have the mindset these days that we're losing that footing a little bit. What's your perspective? Are you concerned about some of the trends that you're seeing? What does your crystal ball tell you? Dr. Jason Westin: I am highly concerned about this. I think as you said, the U.S. has been a leader for a long time, but it wasn't always. This is not something that's preordained that the world-leading clinical research and translational research will always be done in the United States. That is something that has been developed as an ecosystem, as an engine for innovation and for job development, new technology development, since World War II. That's something that through intentional investments in research was developed that the best and brightest around the world, if they could choose to go anywhere, you wanted them to come to work at universities and academic places within the United States. And I think, as you said, that's at risk if you begin to dry up the investment in research or if you begin to have less focus on being engaged in research in a way that is forward thinking, not just kind of maintaining what we do now or only looking at having private, for profit sponsored research. But if you don't have the investment in the basic science research and the translational research and the forward-thinking part of it, the fear is that we lose the advantage and that other countries will say, "Thank you very much," and be happy to invest in ways to their advantage. And I think as you mentioned, there are people that are beginning to look elsewhere. I don't think that it's likely that a significant population of researchers in the U.S. who are established and have careers and families – I don't think that we're going to see a mass exodus of folks. I think the real risk to me is that the younger, up-and-coming people in undergraduate or in graduate school or in medical school and are the future superstars, that they could either choose to go into a different field, so they decide not to go into what could be the latest breakthroughs for cancer patients but could be doing something in AI or something in a different field that could be attractive to them because of less uncertainty about funding streams, or they could take that job offer if it's in a different country. And I think that's the concern is it may not be a 2026 problem, but it could be a 2036 or a 2046 problem that we reap what we sow if we don't invest in the future. Dr. Monty Pal: Indeed, indeed. You know, I've had the pleasure of reviewing abstracts for some of our big international meetings, as I'm sure you've done in the past too. I see this trend where, as before, we would see the preponderance of large phase 3 clinical trials and practice setting studies being done here in the U.S., I'm seeing this emergence of China, of other countries outside of the U.S. really taking lead on these things. And it certainly concerns me. If I had to sort of gauge this particular issue, it's at the top of my list in terms of what I'm concerned about. But I also wanted to ask you, Jason, in terms of the issues that are looming over oncology from an advocacy perspective, what else really sort of keeps you up at night? Dr. Jason Westin: I'm quite concerned about the drug shortages. I think that's something that is a surprisingly evergreen problem. This is something that is on its face illogical that we're talking about the greatest engine for research in the world being the United States and the investment that we've made in drug development and the breakthroughs that have happened for patients all around the world, many of them happen in the United States, and yet we don't necessarily have access to drugs from the 1970s or 1980s that are cheap, generic, sterile, injectable drugs. This is the cisplatins and the vincristines and the fludarabine type medications which are not the sexy ones that you see the ads in the magazine or on TV at night. These are the backbone drugs for many of our curative intent regimens for pediatrics and for heme malignancies and many solid tumors. And the fact that that's continuing to be an issue is, in my opinion, a failure to address the root causes, and those are going to require legislative solutions. The root causes here are basically a race to the bottom where the economics to invest in quality manufacturing really haven't been prioritized. And so it's a race to the cheapest price, which often means you undercut your competitor, and when you don't have the money to invest in good manufacturing processes, the factory breaks down, there's no alternative, you go into shortage. And this has been going on for a couple of decades, and I don't think there's an end in sight until we get a serious solution proposed by our elected officials. That is something that bothers me in the ways where we know what we should be doing for our patients, but if we don't have the drugs, we're left to be creative in ways we shouldn't have to do to figure out a plan B when we've got curative intent therapies. And I think that's a real shame.  There's obviously a lot of other things that are concerning related to oncology, but something that I have personally had experience with when I wanted to give a patient a CAR T-cell, and we don't have a supply of fludarabine, which is a trivial drug from decades ago in terms of the technology investments in genetically modified T-cells, to not then have access to a drug that should be pennies on the dollar and available at any time you want it is almost like the Air Force investing in building the latest stealth bomber, but then forgetting to get the jet fuel in a way that they can't use it because they don't have the tools that they need. And so I think that's something that we do need to have comprehensive solutions from our elected officials. Dr. Monty Pal: Brilliantly stated. I like that analogy a lot. Let's get into the weeds for a second. What would that proposal to Congress look like? What are we trying to put in front of them to help alleviate the drug shortages? Dr. Jason Westin: We could spend a couple hours, and I know podcasts usually are not set up to do that. And so I won't go through every part. I will direct you that there have been a couple of recent publications from ASCO specifically detailing solutions, and there was a recent white paper from the Senate Finance Committee that went through some legislative solutions being explored. So Dr. Gralow, ASCO CMO, and I recently had a publication in JCO OP detailing some solutions, more in that white paper from the Senate Finance. And then there's a working group actually going through ASCO's Health Policy Committee putting together a more detailed proposal that will be published probably around the end of 2026. Very briefly, what needs to happen is for government contracts for purchasing these drugs, there needs to be an outlay for quality, meaning that if you have a manufacturing facility that is able to deliver product on time, reliably, you get a bonus in terms of your contract. And that changes the model to prioritize the quality component of manufacturing. Without that, there's no reason to invest in maintaining your machine or upgrading the technology you have in your manufacturing plant. And so you have bottlenecks emerge because these drugs are cheap, and there's not a profit margin. So you get one factory that makes this key drug, and if that factory hasn't had an upgrade in their machines in 20 years, and that machine conks out and it takes 6 months to repair or replacement, that is an opportunity for that drug to go into shortage and causes a mad dash for big hospitals to purchase the drug that's available, leaving disparities to get amplified. It's a nightmare when those things happen, and they happen all the time. There are usually dozens, if not hundreds, of drugs in shortage at any given time. And this has been going on for decades. This is something that we do need large, system-wide fixes and that investment in quality, I think, will be a key part. Dr. Monty Pal: Yeah, brilliantly said. And I'll make sure that we actually include those articles on the tagline for this podcast as well. I'll talk to our producer about that as well.  I'm really glad you mentioned the time in your last comment there because I felt like we just started, but in fact, I think we're right at our close here, Jason, unfortunately. So, I could have gone on for a couple more hours with you. I really want to thank you for these absolutely terrific insights and thank you for all your advocacy on behalf of ASCO and oncologists at large. Dr. Jason Westin: Thank you so much for having me. I have enjoyed it. Dr. Monty Pal: Thanks a lot. And many thanks to our listeners too. You can find more information about ASCO's advocacy agenda and activities at asco.org. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks so much. ASCO Advocacy Resources: Get involved in ASCO's Advocacy efforts: ASCO Advocacy Toolkit Crisis of Cancer Drug Shortages: Understanding the Causes and Proposing Sustainable Solutions, JCO Oncology Practice Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:     Dr. Monty Pal   @montypal   Dr. Jason Westin @DrJasonWestin   Follow ASCO on social media:      @ASCO on X     ASCO on Bluesky    ASCO on Facebook      ASCO on LinkedIn      Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Jason Westin: Consulting or Advisory Role: Novartis, Kite/Gilead, Janssen Scientific Affairs, ADC Therapeutics, Bristol-Myers Squibb/Celgene/Juno, AstraZeneca, Genentech/Roche, Abbvie, MorphoSys/Incyte, Seattle Genetics, Abbvie, Chugai Pharma, Regeneron, Nurix, Genmab, Allogene Therapeutics, Lyell Immunopharma Research Funding: Janssen, Novartis, Bristol-Myers Squibb, AstraZeneca, MorphoSys/Incyte, Genentech/Roche, Allogene Therapeutics

Joey joins the show to give his thoughts on Monty turning back to Binnington to start vs Boston, and what should we be expecting out of Aleksanteri Kaskimaki in his debut. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

(00:00-13:52) Audio of friend of the show Josh Schertz talking about the Billikens win against Loyola Marymount. Audio of Dennis Gates talking about the technical foul and other things that lead to the loss last night against Notre Dame. Envious of Jackson's passion.(14:00-23:36) They've got a problem in Happy Valley. Kalani Sitaki staying at BYU and Penn State still has no coach. Makes you think maybe Drink was a candidate for the Nittany Lions.(23:46-34:43) Friend of the show Jeremy Rutherford stops by the studio. Did he catch any flack for his F grade for the Blues? Would Minnesota have some interest in Jordan Kyrou? Do the Blues figure to have many Olympic players? JR likes Arby's. JR's take on Binner yapping at Monty.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week, it's grey hair, bare feet, answering phones and the invasive nostril assault of a strong-smelling person. There's also a new show that Monty is dying to watch, Wog v Aussie Christmas lunch duties and we ask - has Christmas gone too far? Enjoy. x Fancy supporting us on Patreon? Find out more here. Follow us and get in touch on Instagram here. Follow us on Facebook here. See omnystudio.com/listener for privacy information.

JR joins the show to talk about Binner and Monty exchanging words on the bench last night and shares what Binner had to say the media after practice today. Plus, JR talks about the impact the injuries to Snuggy, Torpo, and Walker will have on the Blues. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

To support this ministry and help us continue to reach people all around our region, click here: http://bethel.ag/give/Stay Connected Website: www.bethel.ag Bethel Church Facebook: www.facebook.com/bethelchurch605/ Bethel Church Instagram: www.instagram.com/bethelchurch605/

Join Debbie Loucks on a special episode of Horsemanship Radio as she kicks off this new series! Each month, we'll delve into a chapter from Monty Roberts' insightful book, Horse Sense for People. Discover how Monty's revolutionary, non-violent communication techniques with horses offer invaluable lessons for human relationships, business, and personal growth. This series aims to share Monty's timeless wisdom and inspiring stories with everyone, free of charge. Tune in on the 1st and 15th of every month for new episodes of Horsemanship Radio! Horsemanship Radio 292:Show Host: Debbie LoucksTitle Sponsor: HandsOn Gloves, All-In-One Shedding/Bathing/Grooming GlovesPhotos used with permissionPurchase your own copy of Horse Sense for PeopleLearn more about Good Horsemanship at Monty Roberts EQUUS Online University Monty's CalendarPlease follow Monty Roberts on FacebookFollow Monty Roberts on Twitter or on InstagramSee more at: MontyRoberts.comHear all the shows on the Horse Radio NetworkSupport the show

Join Debbie Loucks on a special episode of Horsemanship Radio as she kicks off this new series! Each month, we'll delve into a chapter from Monty Roberts' insightful book, Horse Sense for People. Discover how Monty's revolutionary, non-violent communication techniques with horses offer invaluable lessons for human relationships, business, and personal growth. This series aims to share Monty's timeless wisdom and inspiring stories with everyone, free of charge. Tune in on the 1st and 15th of every month for new episodes of Horsemanship Radio! Horsemanship Radio 292:Show Host: Debbie LoucksTitle Sponsor: HandsOn Gloves, All-In-One Shedding/Bathing/Grooming GlovesPhotos used with permissionPurchase your own copy of Horse Sense for PeopleLearn more about Good Horsemanship at Monty Roberts EQUUS Online University Monty's CalendarPlease follow Monty Roberts on FacebookFollow Monty Roberts on Twitter or on InstagramSee more at: MontyRoberts.comHear all the shows on the Horse Radio NetworkSupport the show

Sermon Notes Date: 11/30/2025 Preacher: Monty Simao, pastor Series: Wisdom and Worship: Walking Through Psalms and Proverbs Key Text: Psalm 15 Description: What kind of person is truly worthy to live in the presence of God? No one. Unless… he is perfectly righteous. Today on Scandia Bible Church Podcast, Pastor Monty Simao takes us to […]

Monty is joined by Baz Richmond and Graeme Johnston -making his pod debut - to dissect the weekend's action and look ahead to the double-header this week.

Episode 583! It's New Japan Catch Up! James, Jaxie, Monty and Gina are here for all things New Japan! We have Dominion and King of Pro Wrestling! Plus lot's more! Enjoy!!

This is a free preview of a paid episode. To hear more, visit andrewsullivan.substack.comMichel is a human rights lawyer and author. He's currently a lecturer at Columbia Law School, where he teaches national security law and jurisprudence. He's also a contributing editor at Lawfare. His latest book is The Light of Battle: Eisenhower, D-Day, and the Birth of the American Superpower — an accessible, racy account of the run-up to D-Day, along with fascinating snapshots of his entire career.For two clips of our convo — why FDR picked Eisenhower to orchestrate D-Day, and why he's the antithesis of Trump — head to our YouTube page.Other topics: Michel raised by a single mom in Allentown who became an Allentown DA; his scholarship to Oxford for computational linguistics; his work on human rights and defending Gitmo detainees; John Adams and due process; the Dish's coverage of torture; the ways Eisenhower was misunderstood; his self-effacement; his religious pacifist parents; his abusive dad; his Horatio Alger story; Kansas conservatism; the knee injury that ended his football stardom at West Point; the scandal that nearly ended his career early on; the scarlet fever that killed his son; his early friendship with Patton; his intellectual mentor Fox Conner; Ike a protege of MacArthur until they soured on each other; his moderation and suspicion of ideology; his workaholism and stoicism; Pearl Harbor; his uneasy relationship with FDR; unexpectedly picked over George Marshall to lead D-Day; his knack for building consensus; winning over Monty and the other Brits; Churchill's antics and his opposition to a Normandy landing; haunted by Gallipoli; the Atlantic Wall; Rommel; shouting matches at the Cairo Conference; Ike's quiet charisma; the alleged affair with his Irish driver Kay Summersby; and how the weather nearly ruined D-Day.Browse the Dishcast archive for an episode you might enjoy. Coming up: George Packer on his Orwell-inspired novel, Shadi Hamid on US power abroad, Simon Rogoff on the narcissism of pols, Jason Willick on trade and conservatism, Vivek Ramaswamy on the right, and Arthur Brooks on the science of happiness. Please send any guest recs, dissents, and other comments to dish@andrewsullivan.com.

Amye and Becca recap and review Landman S2:EP2 Sins of the FatherCami works to uncover Monty's secret, Angela and Ainsley cause a stir at the nursing home, but more importantly, we get a lot of father/son drama with TL, Tommy, and Cooper. For ad-free and BONUS episodes, please support the show by signing up for Little Miss Recap PREMIUM:https://www.patreon.com/littlemissrecap or click subscribe on Apple Podcasts!SUPPORT MY SPONSORS!LUMI GUMMIES are consistent, mellow, and super delicious –– Lumi Gummies are specifically designed to make you feel good, not stoned. Lumi Gummies are available nationwide. We have a 30% code for our listeners! Visit www.LumiGummies.com and use code (LITTLEMISSRECAP) for 30% off your order.Listen to my true crime podcast: Murder She Watched at www.murdershewatchedpod.comGet in touch with us:Facebook: https://www.facebook.com/groups/littlemissrecapFacebook group: https://www.facebook.com/groups/littlemissrecapInstagram: @littlemissrecap Voicemail: www.littlemissrecap.comEmail: amye@littlemissrecap.comGrab yourself some Little Miss Recap merch at: https://littlemissrecap.myshopify.com/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Gibbs or Monty?

Lions vs. Packers keys.

This week, Mel shares a fact related to last week's ep courtesy of a beautiful listener named Nic, and Monty's damp from dipping again. Kourtney Kardashian is selling lollypops that are not for your mouth, Kim K has turned her back on psychics after a recent failure, and Love Island contestants are exchanging a lot of saliva. There's also the sex quote for Machine Gun Kelly that turned Monty right off, and the new rules of nappy changing have left us confused. Enjoy! Fancy supporting us on Patreon? Find out more here. Follow us and get in touch on Instagram here. Follow us on Facebook here.See omnystudio.com/listener for privacy information.

Furf and Monty are back today with another Pulm PEEPs Pearls episode, and discussing the use of methylene blue for patients with septic shock. They review the clinical scenarios when this comes up, the mechanism, some key data, and some … Continue reading →

So much going on! UH loses to UNLV, Cambell/Kamehameha advance to State Championship and all the NFL action! Rams continue their roll, Steelers lose again and KC stays alive in the AFC! Plus, Lakers Front Office moves have Monty excited and Ernie crying!

Andy Cumpstey and Kate Leslie welcome Professor Monty Mythen to his Perioperative Profile. Recorded at the 2025 Evidence Based Perioperative Medicine (EBPOM) meeting in Dingle, Ireland. Monty discusses his fascinating career, from his childhood in London to becoming Professor of Anaesthesia and Intensive Care at University College London. He notes his involvement in founding EBPOM and his role at BD Advanced Patient Monitoring. The conversation covers Monty's groundbreaking research on gut perfusion and multiple organ failure, his high-altitude research expeditions to Mount Everest, and his transition to a role in the healthcare industry. He shares insights on the intricate process of medical device approval. The episode is a deep dive into the experiences and achievements of a leading medical mind.

To support this ministry and help us continue to reach people all around our region, click here: http://bethel.ag/give/Stay Connected Website: www.bethel.ag Bethel Church Facebook: www.facebook.com/bethelchurch605/ Bethel Church Instagram: www.instagram.com/bethelchurch605/

The legendary Lynsey Mac joins Monty for this week's pod as they debrief Saturday's defeat at home to Motherwell

Sermon Notes Date: 11/23/2025 Preacher: Josh Peglow, pastor Series: Colossians Key Text: Colossians 3:5-11 Description: “Thou shalt not kill.” We all know the commandment. But in Colossians 3, Paul throws us a curveball: When it comes to your old self — YOU MUST KILL. Today on Scandia Bible Church Podcast, Pastor Josh Peglow continues our […]

November 19th, 2025 We gather up the brain trust of the Sweet Spot (Sean Bass & David Mino) & the Hardline back from Las Vegas (Corby Davidson, Bob Sturm & Dave Lane) led by Monty to give us birthdays, shoutouts, 'on this day in history' and any other nuggets to show you Why Today Doesn't Suck. Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket’s Website And follow The Ticket Top 10 on Apple, Spotify or Amazon MusicSee omnystudio.com/listener for privacy information.

November 18th, 2025 We gather up the brain trust of the Sweet Spot (Sean Bass & David Mino) & the Hardline live from Las Vegas at Circa(Corby Davidson, Bob Sturm & Dave Lane) led by Monty to give us birthdays, shoutouts, 'on this day in history' and any other nuggets to show you Why Today Doesn't Suck. Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket’s Website And follow The Ticket Top 10 on Apple, Spotify or Amazon MusicSee omnystudio.com/listener for privacy information.

Bestselling author, Jamie Day, discusses his suspenseful new release, THE LAKE ESCAPE. An annual friend's trip to the lake takes a dark turn when the woman one of them is dating disappears. Suspicion abounds and friendships are tested as each of the remaining friends wonders if the next lake tragedy will be their own. “A master storyteller with wit and style.” —William Landay, New York times bestselling author Listen in as we chat about the importance of collaboration, why hope matters, and find out how I became an instant fan of an awesome pup named Monty as well as Greta the Bookish Chiweenie! (Non book-related spoiler: Monty makes a couple of cameos in the video version of this interview on You Tube. Prepare to melt!) https://www.mariesutro.com/twisted-passages-podcast ABOUT THE AUTHOR: Jamie Day lives in one of those picture-perfect, coastal New England towns you see in the movies. And just like the movies, Jamie has two children and an adorable dog to fawn over. When not writing or reading, Jamie enjoys yoga, the ocean, cooking, and long walks on the beach with the dog, or the kids, or sometimes both.

November 17th, 2025 We gather up the brain trust of the Sweet Spot (Sean Bass & David Mino) & the Hardline live from Las Vegas (Corby Davidson, Bob Sturm & Dave Lane) led by Monty to give us birthdays, shoutouts, 'on this day in history' and any other nuggets to show you Why Today Doesn't Suck. Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket’s Website And follow The Ticket Top 10 on Apple, Spotify or Amazon MusicSee omnystudio.com/listener for privacy information.

Sermon Notes Date: 11/16/2025 Preacher: Monty Simao, pastor Series: Wisdom and Worship: Walking Through Psalms and Proverbs Key Text: Proverbs 28:13 Description: When our sin feels too heavy to face, we all have places we run. We cover. We excuse. We delay. We bury what we hope will simply disappear in the dark. But concealed […]

November 14th, 2025 We gather up the brain trust of the Sweet Spot (Sean Bass & David Mino) & the Hardline (Corby Davidson, Bob Sturm & Dave Lane) led by Monty to give us birthdays, shoutouts, 'on this day in history' and any other nuggets to show you Why Today Doesn't Suck. Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket’s Website And follow The Ticket Top 10 on Apple, Spotify or Amazon MusicSee omnystudio.com/listener for privacy information.

Debbie sits down with Michael Cox who writes about horses in Hong Kong and Japan. Michael attended a Monty's Special Training to learn what the renowned trainer knows about the direction of horse racing. Listen in on his provocative findings...Horsemanship Radio 291:Show Host: Debbie LoucksTitle Sponsor: HandsOn Gloves, All-In-One Shedding/Bathing/Grooming GlovesPhotos used with permissionLearn more about Good Horsemanship at Monty Roberts EQUUS Online University Monty's CalendarPlease follow Monty Roberts on FacebookFollow Monty Roberts on Twitter or on InstagramSee more at: MontyRoberts.comHear all the shows on the Horse Radio NetworkSupport the show

Debbie sits down with Michael Cox who writes about horses in Hong Kong and Japan. Michael attended a Monty's Special Training to learn what the renowned trainer knows about the direction of horse racing. Listen in on his provocative findings...Horsemanship Radio 291:Show Host: Debbie LoucksTitle Sponsor: HandsOn Gloves, All-In-One Shedding/Bathing/Grooming GlovesPhotos used with permissionLearn more about Good Horsemanship at Monty Roberts EQUUS Online University Monty's CalendarPlease follow Monty Roberts on FacebookFollow Monty Roberts on Twitter or on InstagramSee more at: MontyRoberts.comHear all the shows on the Horse Radio NetworkSupport the show

November 13th, 2025 We gather up the brain trust of the Sweet Spot (Sean Bass & David Mino) & the Hardline (Corby Davidson, Bob Sturm & Dave Lane) led by Monty to give us birthdays, shoutouts, 'on this day in history' and any other nuggets to show you Why Today Doesn't Suck. Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket’s Website And follow The Ticket Top 10 on Apple, Spotify or Amazon MusicSee omnystudio.com/listener for privacy information.

Robert Thomas joins us for his long-awaited return to TMA. Robert talks about how the team has arrived to this spot and the mindset it will take to get back to winning ways. Robert also talks about the rock music that Monty was playing. Robert then discusses the injury situation with Neighbours, goaltending, and the outlook on the next few weeks. Finally, we talk about Robert's wedding over the offseason. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

(00:00-38:57) Oooh, I must be hittin' a growth spurt. Thursday Throwdown. Welcome back, Bob. Like a fortress. Fight Tiger (basketball). We're like five presidents just sittin' around. The Irish guy comes through, make a note. This planet's not gonna be around much longer. Doug, do you want Steve in Wildwood or Dan Janson? Let's hear from Steve first. Rene Knott got hit by a bus. No room at Algonquin. Doug, you think Wellington's hot? Bracketology in November. Half my sons. Tufts for seniors. The Polar Express and Rumpleminze Santa. Even bums get presents. Timestamps.(39:05-52:18) Showtune Thursday. Mizzou's National Championship path. Audio of Florida interim coach Billy Gonzales being asked if Lane Kiffin would be a good fit at Florida. Good non-answer. Why'd you send the money, Lix? Shoutout the listener who sent Jackson tickets for the Mizzou game. There's a shrub on the dais. Who has blonde shrubs? Infidelity by the wayside.(52:28-1:11:42) Great to be reunited with Robert Thomas. Robert's assessment of the Blues' slow start. What does the team need to do to get back to their winning ways? Monty's playlist. Missing Jake Neighbours. Getting over the Game 7 loss to the Jets last year. The Tkachuk boys starting a podcast. Big life changes off the ice.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

November 12th, 2025 We gather up the brain trust of the Sweet Spot (Sean Bass & David Mino) & the Hardline (Corby Davidson, Bob Sturm & Dave Lane) led by Monty to give us birthdays, shoutouts, 'on this day in history' and any other nuggets to show you Why Today Doesn't Suck. Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket’s Website And follow The Ticket Top 10 on Apple, Spotify or Amazon MusicSee omnystudio.com/listener for privacy information.

November 11th, 2025 We gather up the brain trust of the Sweet Spot (Sean Bass & David Mino) & the Hardline (Corby Davidson, Bob Sturm & Dave Lane) led by Monty to give us birthdays, shoutouts, 'on this day in history' and any other nuggets to show you Why Today Doesn't Suck. Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket’s Website And follow The Ticket Top 10 on Apple, Spotify or Amazon MusicSee omnystudio.com/listener for privacy information.

November 10th, 2025 We gather up the brain trust of the Sweet Spot (Sean Bass & David Mino) & the Hardline (Corby Davidson, Bob Sturm & Dave Lane) led by Monty to give us birthdays, shoutouts, 'on this day in history' and any other nuggets to show you Why Today Doesn't Suck. Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket’s Website And follow The Ticket Top 10 on Apple, Spotify or Amazon MusicSee omnystudio.com/listener for privacy information.

Monty Makes A Temperature Confession To DJ Ringgenberg and Matt Bermingham. The Crew Also Discuss Ham's War With Parking Attendant. 11-10-2025 Listen to past episodes on The Ticket’s Website And follow The Ticket Top 10 on Apple, Spotify or Amazon Music See omnystudio.com/listener for privacy information.

November 7th, 2025 Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket’s Website And follow The Ticket Top 10 on Apple, Spotify or Amazon MusicSee omnystudio.com/listener for privacy information.

November 7th, 2025 Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket’s Website And follow The Ticket Top 10 on Apple, Spotify or Amazon MusicSee omnystudio.com/listener for privacy information.